Acridine derivatives activate p53 and induce tumor cell death through bax

CP-31398 activates wild-type p53 by a novel mechanism that does not involve phosphorylation of the amino-terminus of p53 and disassociation of MDM2. To identify more potent CP-31398-like p53 activators, we synthesized 4 acridine derivatives with a similar structure to CP-31398. These four compounds induced strong p53 transcription in cells with wild-type p53. We also found that several randomly chosen acridine derivatives, including 9- aminoacridine, amsacrine, quinacrine and acridine orange, induced p53 transcriptional activity. All these acridine derivatives stabilized p53 protein by blocking its ubiquitination, without phosphorylation of ser15 or ser20 on p53. Furthermore, acridine derivatives induced p53-dependent cell death. Knockout of Bax, a p53 target and a key cell death inducer in both intrinsic and extrinsic apoptotic pathways, blocked acridine derivatives from inducing cell death. In addition, in vivo delivery of quinacrine and amsacrine induced p53 transcriptional activity in tumor xenografts. Our results reveal that DNA-intercalating acridine derivatives can induce p53 stabilization by a manner similar to CP-31398. These findings provide insights into p53 regulation in response to DNA intercalating drugs and may assist new anticancer drug design.

[1]  P. Stanhope-Baker,et al.  The Wilms Tumor Suppressor-1 Target Gene Podocalyxin Is Transcriptionally Repressed by p53* , 2004, Journal of Biological Chemistry.

[2]  W. Denny,et al.  Dual topoisomerase I/II inhibitors in cancer therapy. , 2003, Current topics in medicinal chemistry.

[3]  Yoichi Taya,et al.  DNA Damage-Induced Phosphorylation of p53 Alleviates Inhibition by MDM2 , 1997, Cell.

[4]  E. Stavridi,et al.  Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[5]  K. Vousden,et al.  Stress Signals Utilize Multiple Pathways To Stabilize p53 , 2000, Molecular and Cellular Biology.

[6]  W. El-Deiry,et al.  The Mutant p53-Conformation Modifying Drug, CP-31398, Can Induce Apoptosis , 2002, Cancer biology & therapy.

[7]  K. Kinzler,et al.  p53 tagged sites from human genomic DNA. , 1994, Human molecular genetics.

[8]  Stephen N. Jones,et al.  Regulation of p53 stability by Mdm2 , 1997, Nature.

[9]  Shengyun Fang,et al.  Mdm2 Is a RING Finger-dependent Ubiquitin Protein Ligase for Itself and p53* , 2000, The Journal of Biological Chemistry.

[10]  P. Herrlich,et al.  DNA damage induced p53 stabilization: no indication for an involvement of p53 phosphorylation , 1999, Oncogene.

[11]  Michael Weller,et al.  Predicting response to cancer chemotherapy: the role of p53 , 1998, Cell and Tissue Research.

[12]  M. Oren,et al.  Mdm2 promotes the rapid degradation of p53 , 1997, Nature.

[13]  R Montesano,et al.  Database of p53 gene somatic mutations in human tumors and cell lines. , 1994, Nucleic acids research.

[14]  M. Blagosklonny Loss of function and p53 protein stabilization , 1997, Oncogene.

[15]  D. Durocher,et al.  DNA-PK, ATM and ATR as sensors of DNA damage: variations on a theme? , 2001, Current opinion in cell biology.

[16]  R. Honda,et al.  Association of p19ARF with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53 , 1999, The EMBO journal.

[17]  W. El-Deiry,et al.  Cell cycle control as a basis for cancer drug development (Review). , 2000, International journal of oncology.

[18]  D. Meek,et al.  Critical roles for the serine 20, but not the serine 15, phosphorylation site and for the polyproline domain in regulating p53 turnover. , 2001, The Biochemical journal.

[19]  L. Latonen,et al.  UV-radiation induces dose-dependent regulation of p53 response and modulates p53-HDM2 interaction in human fibroblasts , 2001, Oncogene.

[20]  J. Lucci,et al.  A Phase II Trial of Pyrazoloacridine (PZA) in Squamous Carcinoma of the Cervix – A Gynecologic Oncology Group Study , 2001, Investigational New Drugs.

[21]  M. Demma,et al.  CP-31398 Restores DNA-binding Activity to Mutant p53 in Vitro but Does Not Affect p53 Homologs p63 and p73* , 2004, Journal of Biological Chemistry.

[22]  T. Unger,et al.  Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2 , 1999, The EMBO journal.

[23]  G. Stark,et al.  Phosphorylation of serines 15 and 37 is necessary for efficient accumulation of p53 following irradiation with UV , 2001, Oncogene.

[24]  F. Charmantray,et al.  Interest of acridine derivatives in the anticancer chemotherapy. , 2001, Current pharmaceutical design.

[25]  F. Zindy,et al.  Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[26]  C. Maki,et al.  The MDM2 RING-finger domain is required to promote p53 nuclear export , 2000, Nature Cell Biology.

[27]  C. Maki,et al.  MDM2-dependent ubiquitination of nuclear and cytoplasmic P53 , 2000, Oncogene.

[28]  D. V. Hoff,et al.  m-AMSA and PALA: Two new agents in cancer chemotherapy , 2004, Cancer Chemotherapy and Pharmacology.

[29]  M. Blagosklonny,et al.  P53: An ubiquitous target of anticancer drugs , 2002, International journal of cancer.

[30]  A. Barberis,et al.  CP-31398, a putative p53-stabilizing molecule tested in mammalian cells and in yeast for its effects on p53 transcriptional activity , 2004, Journal of Negative Results in Biomedicine.

[31]  P. Howley,et al.  In vivo ubiquitination and proteasome-mediated degradation of p53(1). , 1996, Cancer research.

[32]  D. Lacombe,et al.  Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancer* , 2003, Investigational New Drugs.

[33]  W. El-Deiry,et al.  Stabilization of p53 by CP-31398 Inhibits Ubiquitination without Altering Phosphorylation at Serine 15 or 20 or MDM2 Binding , 2003, Molecular and Cellular Biology.

[34]  B. Foster,et al.  Pharmacological rescue of mutant p53 conformation and function. , 1999, Science.

[35]  W. el-Deiry,et al.  Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling , 2001, Cell Death and Differentiation.

[36]  K. Parang,et al.  Current targets for anticancer drug discovery. , 2003, Current drug targets.

[37]  D. Lane,et al.  Cocompartmentalization of p53 and Mdm2 is a major determinant for Mdm2-mediated degradation of p53. , 2001, Experimental cell research.

[38]  F. Valea,et al.  A phase II trial of pyrazoloacridine (PZA) in squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study , 2002, Cancer Chemotherapy and Pharmacology.

[39]  Wafik S El-Deiry,et al.  Bioluminescent Molecular Imaging of Endogenous and Exogenous p53-Mediated Transcription In Vitro and In Vivo Using an HCT116 Human Colon Carcinoma Xenograft Model , 2003, Cancer biology & therapy.

[40]  Galina Selivanova,et al.  Characterization of the p53-rescue drug CP-31398 in vitro and in living cells , 2002, Oncogene.

[41]  W. Denny,et al.  Acridine derivatives as chemotherapeutic agents. , 2002, Current medicinal chemistry.